Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) gapped up before the market opened on Thursday . The stock had previously closed at $6.35, but opened at $6.35. Aldeyra Therapeutics shares last traded at $8.41, with a volume of 3,000,211 shares.

ALDX has been the topic of a number of research analyst reports. HC Wainwright set a $18.00 price target on Aldeyra Therapeutics and gave the stock a “buy” rating in a research note on Thursday, June 15th. ValuEngine lowered Aldeyra Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 6th. Cowen and Company restated an “outperform” rating and set a $14.00 price target (up previously from $9.00) on shares of Aldeyra Therapeutics in a research note on Thursday. Canaccord Genuity restated a “buy” rating and set a $27.00 price target (up previously from $12.00) on shares of Aldeyra Therapeutics in a research note on Wednesday. Finally, Zacks Investment Research lowered Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 30th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $15.95.

The firm’s market cap is $55.58 million. The firm has a 50 day moving average price of $4.74 and a 200 day moving average price of $4.75.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.02. Equities research analysts forecast that Aldeyra Therapeutics, Inc. will post ($1.63) EPS for the current fiscal year.

In other Aldeyra Therapeutics news, major shareholder Life Sciences Maste Perceptive acquired 296,007 shares of the company’s stock in a transaction dated Friday, June 30th. The shares were acquired at an average price of $4.60 per share, for a total transaction of $1,361,632.20. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 28.40% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC grew its stake in Aldeyra Therapeutics by 48.7% during the 1st quarter. Perceptive Advisors LLC now owns 2,885,458 shares of the biotechnology company’s stock worth $12,897,000 after buying an additional 945,000 shares during the last quarter. Sphera Funds Management LTD. grew its stake in Aldeyra Therapeutics by 31.0% during the 2nd quarter. Sphera Funds Management LTD. now owns 875,931 shares of the biotechnology company’s stock worth $4,117,000 after buying an additional 207,431 shares during the last quarter. Vanguard Group Inc. grew its stake in Aldeyra Therapeutics by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after buying an additional 9,407 shares during the last quarter. Sabby Management LLC purchased a new position in Aldeyra Therapeutics during the 1st quarter worth approximately $898,000. Finally, Hikari Power Ltd grew its stake in Aldeyra Therapeutics by 186.4% during the 2nd quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock worth $507,000 after buying an additional 70,196 shares during the last quarter. Hedge funds and other institutional investors own 49.09% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Aldeyra Therapeutics, Inc. (ALDX) Shares Gap Up to $6.35” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/16/aldeyra-therapeutics-inc-aldx-shares-gap-up-to-6-35.html.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.